Pegilodecakin alone or in combination for heavily pre-treated advanced kidney cancer patients

This study looked at the use of pegilodecakin alone or in combination with immunotherapy or targeted therapy for the treatment of people with advanced solid tumours. Pegilodecakin is a form of cytokine called interleukin-10. The interleukin-10 is attached to a substance called polyethylene glycol (PEG) to improve how the drug works to unleash the immune […]

read more

Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer

A recent phase 1b clinical trial investigated the use of pegilodecakin in combination with anti-PD-1 monoclonal antibodies nivolumab or pembrolizumab. The combination showed a “favourable” response in patients with non-small cell lung cancer and kidney cancer. Pegilodecakin works by stimulating the survival, proliferation and “killing” potential of CD8+ T cells, which can recognise and destroy […]

read more
Showing all 2 results
  TOP